Department of Clinical Medicine, Aarhus University (Rohde, Østergaard, Jefsen), and Department of Affective Disorders (Rohde, Østergaard, Jefsen) and Psychosis Research Unit (Jefsen), Aarhus University Hospital-Psychiatry, Aarhus, Denmark.
Am J Psychiatry. 2024 Jul 1;181(7):630-638. doi: 10.1176/appi.ajp.20230477.
Antidepressants are commonly used to treat bipolar depression but may increase the risk of mania. The evidence from randomized controlled trials, however, is limited by short treatment durations, providing little evidence for the long-term risk of antidepressant-induced mania. The authors performed a target trial emulation to compare the risk of mania among individuals with bipolar depression treated or not treated with antidepressants over a 1-year period.
The authors emulated a target trial using observational data from nationwide Danish health registers. The study included 979 individuals with bipolar depression recently discharged from a psychiatric ward. Of these, 358 individuals received antidepressant treatment, and 621 did not. The occurrence of mania and bipolar depression over the following year was ascertained, and the intention-to-treat effect of antidepressants was analyzed by using Cox proportional hazards regression with adjustment for baseline covariates to emulate randomized open-label treatment allocation.
The fully adjusted analyses revealed no statistically significant associations between treatment with an antidepressant and the risk of mania in the full sample (hazard rate ratio=1.08, 95% CI=0.72-1.61), in the subsample concomitantly treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.63-2.13), and in the subsample not treated with a mood-stabilizing agent (hazard rate ratio=1.16, 95% CI=0.65-2.07). Secondary analyses revealed no statistically significant association between treatment with an antidepressant and bipolar depression recurrence.
These findings suggest that the risk of antidepressant-induced mania is negligible and call for further studies to optimize treatment strategies for individuals with bipolar depression.
抗抑郁药常用于治疗双相情感障碍抑郁发作,但可能会增加躁狂的风险。然而,随机对照试验的证据受到治疗持续时间短的限制,对抗抑郁药引起躁狂的长期风险几乎没有证据。作者进行了一项靶向试验模拟,以比较在一年内有双相情感障碍抑郁发作的个体接受或不接受抗抑郁药治疗的躁狂风险。
作者使用来自全国丹麦健康登记处的观察性数据模拟了一项靶向试验。该研究纳入了 979 名最近从精神病病房出院的双相情感障碍抑郁发作患者。其中 358 名患者接受了抗抑郁治疗,621 名患者未接受治疗。确定了以下一年内躁狂和双相情感障碍的发生情况,并通过使用 Cox 比例风险回归进行意向治疗分析,调整基线协变量,以模拟随机开放标签治疗分配。
完全调整后的分析显示,在全样本中(危险率比=1.08,95%CI=0.72-1.61),在同时接受情绪稳定剂治疗的亚样本中(危险率比=1.16,95%CI=0.63-2.13),以及在未接受情绪稳定剂治疗的亚样本中(危险率比=1.16,95%CI=0.65-2.07),抗抑郁治疗与躁狂风险之间没有统计学上显著的关联。二次分析显示,抗抑郁治疗与双相情感障碍复发之间没有统计学上显著的关联。
这些发现表明,抗抑郁药引起躁狂的风险可以忽略不计,需要进一步的研究来优化双相情感障碍患者的治疗策略。